Given the considerable influence of the tumor immune microenvironment on immune checkpoint blockade (ICB) therapy, we investigated the prognostic roles of NEK2 in pancreatic cancers with different immune statuses. The gene discussed is NEK2; the disease is familial pancreatic carcinoma.